Ethical reflections on phase I clinical trials of anticancer drugs: from a Chinese IRB’s empirical perspective
Abstract Purpose With the rapid development of Phase I clinical trials for anticancer drugs in China, addressing ethical concerns is imperative. In order to safeguard the rights, interests, and well-being of research participants, this paper aims to illustrate vital ethical issues that should not be...
Saved in:
| Main Authors: | Xiaoling Liu, Zhengbo Song, Shuting Tang, Zhaochen Wang, Ji Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Holistic Integrative Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44178-024-00126-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
QR codes and international databases: promoting transparency in IRB approvals for medical research
by: Lamia Ben Ezzdine, et al.
Published: (2024-12-01) -
Marine natural products as a source of novel anticancer drugs: an updated review (2019–2023)
by: Hesham R. El-Seedi, et al.
Published: (2025-01-01) -
Ethical aspects of clinical trials in Russia and BRICS countries: an overview
by: Sergey Y. Simeniv, et al.
Published: (2024-09-01) -
Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs
by: Torić Jelena, et al.
Published: (2019-12-01) -
Targeting the cyclin-dependent kinase family in anticancer drug discovery: From computational to experimental studies
by: Priyanka Solanki, et al.
Published: (2024-12-01)